Valuation: Resverlogix Corp.

Market Cap 1.96Cr 1.39Cr 1.24Cr 1.15Cr 1.04Cr 131.36Cr 1.98Cr 14Cr 5.4Cr 69Cr 5.22Cr 5.11Cr 220.03Cr P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 11Cr 7.49Cr 6.68Cr 6.18Cr 5.59Cr 706.9Cr 11Cr 74Cr 29Cr 371.57Cr 28Cr 28Cr 1.18TCr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.44%
Yield 2024 *
-
Yield 2025 -
1 week-5.88%
Current month-11.11%
1 month-11.11%
3 months-20.00%
6 months-23.81%
Current year-20.00%
1 week 0.08
Extreme 0.08
0.08
1 month 0.08
Extreme 0.08
0.12
Current year 0.08
Extreme 0.08
0.14
1 year 0.08
Extreme 0.08
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Date Insider Type Main position Quantity % Market Cap. Importance
06/07/26 Option

Chief Financial Officer

3,50,000 0.1018%
06/07/26 Option

Chief Financial Officer

-3,50,000 0.1018%
06/07/26 Option

Chief Executive Officer

5,00,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.88%-23.81%+14.29% 1.96Cr
-0.21%-4.43%+44.40%+74.13% 6.62TCr
+0.82%+5.41%+8.05%+73.53% 5.52TCr
-0.22%+6.53%+11.68%+87.32% 5.28TCr
+3.28%+5.58%+26.51%+50.05% 4.55TCr
+0.51%+9.95%+22.40%+133.92% 4.39TCr
-1.15%+0.39%+263.21%+594.60% 4.16TCr
+0.10%+9.90%+16.11%+59.33% 3.4TCr
-7.13%-5.67%+28.08%-0.59% 2.58TCr
+0.69%+5.60%+36.60%+26.94% 2.35TCr
Average -0.33%+3.08%+43.32%+111.35% 3.89TCr
Weighted average by Cap. -0.05%+3.72%+49.62%+126.42%

Financials

2024 2025
Net sales - -
Net income -76.35L -54.28L -48.37L -44.78L -40.52L -51Cr -77.25L -5.37Cr -2.11Cr -27Cr -2.04Cr -1.99Cr -86Cr -77.67L -55.22L -49.2L -45.55L -41.23L -52Cr -78.59L -5.46Cr -2.14Cr -27Cr -2.07Cr -2.03Cr -87Cr
Net Debt 8.19Cr 5.82Cr 5.19Cr 4.8Cr 4.35Cr 549.25Cr 8.28Cr 58Cr 23Cr 288.7Cr 22Cr 21Cr 919.97Cr 8.58Cr 6.1Cr 5.43Cr 5.03Cr 4.55Cr 575.54Cr 8.68Cr 60Cr 24Cr 302.52Cr 23Cr 22Cr 964.01Cr
Projected Income Statement - Annual - Resverlogix Corp.
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
21/26/21 CA$0.0800 0.00% 48,000
20/26/20 CA$0.0800 -5.88% 5,000
19/26/19 CA$0.0850 +6.25% 3,000
16/26/16 CA$0.0800 -5.88% 63,264
15/26/15 CA$0.0850 0.00% 3,000